Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy

被引:72
作者
Alam, M
Goldberg, LH
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Div Cutaneous & Aesthet Surg, Chicago, IL 60611 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Med Dermatol, Houston, TX 77030 USA
[3] Dermsurg Associates, Houston, TX USA
关键词
D O I
10.1046/j.1524-4725.2002.02085.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND. Antithrombotic medications may increase perioperative bleeding during cutaneous surgery. Whether to discontinue these medications before surgery is controversial. OBJECTIVE. To evaluate the available evidence in order to generate preliminary guidelines regarding the perioperative use of antithrombotics. METHODS. Presentation of two cases of adverse events after preoperative discontinuation of antithrombotics, review of current anticoagulant and antiplatelet drugs, and review of the literature concerning perioperative antithrombotics in cutaneous surgery. RESULTS. Perioperative withholding of antithrombotics in cutaneous surgery may be associated with serious adverse vascular events. Continuing antithrombotics in these circumstances does not appear to significantly increase bleeding complications. The complexity of available antithrombotics makes case-by-case determinations regarding their use difficult. CONCLUSION. Cutaneous surgeons should strongly consider perioperative continuation of patients' antithrombotic drugs. The final determination should be made by the surgeon after evaluation of the circumstances and, if necessary, consultation with other experts.
引用
收藏
页码:992 / 998
页数:7
相关论文
共 71 条
[1]  
Akhtar W, 1998, AM FAM PHYSICIAN, V58, P130
[2]   Cutaneous surgery in patients receiving warfarin therapy [J].
Alcalay, J .
DERMATOLOGIC SURGERY, 2001, 27 (08) :756-758
[3]   Low-molecular-weight heparins - An intriguing new twist with profound implications [J].
Antman, EM ;
Handin, R .
CIRCULATION, 1998, 98 (04) :287-289
[4]   Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].
Antman, EM ;
McCabe, CH ;
Gurfinkel, EP ;
Turpie, AGG ;
Bernink, PJLM ;
Salein, D ;
de Luna, AB ;
Fox, K ;
Lablanche, JM ;
Radley, D ;
Premmereur, J ;
Braunwald, E .
CIRCULATION, 1999, 100 (15) :1593-1601
[5]   Stenting for ischemic heart disease [J].
Belli, G ;
Ellis, SG ;
Topol, EJ .
PROGRESS IN CARDIOVASCULAR DISEASES, 1997, 40 (02) :159-182
[6]   Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents - A prospective study [J].
Billingsley, EM ;
Maloney, ME .
DERMATOLOGIC SURGERY, 1997, 23 (05) :381-383
[7]   Management of atrial fibrillation in adults: Prevention of thromboembolism and symptomatic treatment [J].
Blackshear, JL ;
Kopecky, SL ;
Litin, SC ;
Safford, RE ;
Hammill, SC .
MAYO CLINIC PROCEEDINGS, 1996, 71 (02) :150-160
[8]   Antiplatelet drugs: How to select them and possibilities of combined treatment [J].
Bornstein, NM .
CEREBROVASCULAR DISEASES, 2001, 11 :96-99
[9]   ASPIRIN, SULFINPYRAZONE, OR BOTH IN UNSTABLE ANGINA - RESULTS OF A CANADIAN MULTICENTER TRIAL [J].
CAIRNS, JA ;
GENT, M ;
SINGER, J ;
FINNIE, KJ ;
FROGGATT, GM ;
HOLDER, DA ;
JABLONSKY, G ;
KOSTUK, WJ ;
MELENDEZ, LJ ;
MYERS, MG ;
SACKETT, DL ;
SEALEY, BJ ;
TANSER, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (22) :1369-1375
[10]  
Chan WS, 1999, HAEMOSTASIS, V29, P105